Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study-Reference-Cited by-同舟云学术

Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study

Published:2017-02-07 Issue:3 Volume:19 Page:401-411
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Knapen Lotte M.¹²,de Jong Roy G. P. J.³⁴⁵,Driessen Johanna H. M.¹²⁵,Keulemans Yolande C.⁶,van Erp Nielka P.⁷,De Bruin Marie L.⁵,Leufkens Hubert G. M.⁵,Croes Sander¹²,de Vries Frank¹²⁵⁸

Affiliation:

1. Department of Clinical Pharmacy and Toxicology; Maastricht University Medical Centre+; Maastricht The Netherlands

2. CAPHRI Care and Public Health Research Institute; Maastricht University Medical Centre+; Maastricht The Netherlands

3. Department of Internal Medicine; VieCuri Medical Centre; Venlo The Netherlands

4. GROW School for Oncology and Developmental Biology; Maastricht University Medical Centre+; Maastricht The Netherlands

5. Department of Pharmacoepidemiology and Clinical Pharmacology; Utrecht Institute for Pharmaceutical Sciences; Utrecht The Netherlands

6. Department of Gastroenterology; Zuyderland Medical Centre; Heerlen The Netherlands

7. Department of Pharmacy; Radboud University Medical Centre; Nijmegen The Netherlands

8. MRC Lifecourse Epidemiology Unit, Southampton General Hospital; University of Southampton; Southampton UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12833/fullpdf

Reference47 articles.

1. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits;Drucker;Diabetes Care,2010

2. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?;Butler;Diabetes Care,2013

3. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies;Elashoff;Gastroenterology,2011

4. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

5. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study;Thomsen;Diabetes Care,2015

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Insights into Chronic Pancreatitis: Potential Mechanisms Related to Probiotics;Microorganisms;2024-08-24

2. Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety study;Pharmacoepidemiology and Drug Safety;2024-05

3. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials;Expert Opinion on Drug Safety;2023-11-20

4. Acute Pancreatitis in a Patient Taking Semaglutide;Cureus;2023-08-19

5. An ethnopharmacology study of Indonesian medicinal plants in Gunung Sari village as dipeptidyl peptidase-IV inhibitor;Pharmacia;2023-06-05